Clinical Trials

Aurora kinase inhibitor impacts relevant biomarker in phase I cancer study

Published in Cancer Weekly, January 17th, 2006

Patients with solid tumor cancers dosing with VX-680 (MK-0457) demonstrated activity on a clinically relevant biomarker in a phase I clinical study, Vertex Pharmaceuticals Incorporated (VRTX) announced.

The report indicates clinical and research progress and triggers the achievement of a milestone in Vertex's contractual collaboration with Merck & Co., Inc. to develop aurora kinase inhibitors for the treatment of cancer.

VX-680 is a small molecule inhibitor of aurora kinases and the lead development compound in the collaboration. In addition, Merck has selected a follow-on compound for development from a joint aurora kinase research program that is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-01-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry